The short answer
Dipeptidyl peptidase-4 cleaves the first two amino acids from the N-terminus of GLP-1 and GIP, inactivating both within one to two minutes. Every long-acting incretin analogue is built to defeat this enzyme, usually by substituting the residue it recognises and adding a fatty-acid chain that binds albumin.
Key facts
- Enzyme
- Dipeptidyl peptidase-4 (DPP-4, CD26)
- Action
- Removes N-terminal dipeptide
- Native GLP-1 half-life
- 1-2 minutes
- Cleavage site
- After position 2 (Ala8 in GLP-1 numbering)
- Peptide countermeasure
- Aib substitution at position 8
- Second countermeasure
- Albumin-binding fatty diacid
- Small-molecule route
- No peptide bonds (not a substrate)
What the enzyme does
DPP-4 is a serine exopeptidase found on cell surfaces and circulating in plasma. It removes dipeptides from the N-terminus of substrates carrying alanine or proline at the second position. GLP-1 and GIP both qualify, and both lose their receptor activity the moment those two residues are gone. The cleaved fragment is not merely weaker. It is inactive.
The first countermeasure: change the residue
If DPP-4 recognises alanine at that position, replace it with something the enzyme cannot process. Semaglutide substitutes α-aminoisobutyric acid (Aib) at position 8. Aib is a non-proteinogenic amino acid with a quaternary alpha carbon, and DPP-4 cannot accommodate it. This single change converts the peptide from a substrate into a non-substrate.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
The second countermeasure: hide in plain sight
Blocking DPP-4 solves enzymatic clearance but not renal clearance, and a peptide of this size is still filtered rapidly. Attaching a fatty diacid chain that binds reversibly to serum albumin solves both: the bound complex is too large to filter and is physically shielded. Chain length tunes the result. Liraglutide's C16 gives roughly daily dosing, semaglutide's C18 diacid and retatrutide's C20 diacid give weekly.
Why this is not the same as a DPP-4 inhibitor
Sitagliptin and its relatives are DPP-4 inhibitors: they block the enzyme so endogenous GLP-1 survives longer. That raises native GLP-1 into a modest physiological range. A GLP-1 receptor agonist instead supplies an engineered ligand at pharmacological concentrations. Both act on the same axis, and the difference in achievable effect size is very large.
How small molecules sidestep the whole problem
Orforglipron and aleniglipron have no peptide bonds. DPP-4 is a peptidase, and a molecule with no amide backbone is not a substrate for it in any sense. There is nothing to cleave. Neither Aib substitution nor albumin binding is needed, because the vulnerability those modifications exist to patch was never present.
Why this shapes almost every molecule in the class
Look at semaglutide, liraglutide, tirzepatide and retatrutide together and the same two features recur: a modified position-8 residue and a lipid chain for albumin binding. That is not convergent coincidence. It is four solutions to one enzyme, and it explains why these molecules look structurally similar despite differing in receptor targets.
Frequently asked questions
What is Aib?
α-aminoisobutyric acid, a non-proteinogenic amino acid. Its quaternary alpha carbon prevents DPP-4 from cleaving the peptide.
Do small molecules need DPP-4 protection?
No. Orforglipron and aleniglipron contain no peptide bonds, so DPP-4 has nothing to act on.
Is a DPP-4 inhibitor the same as a GLP-1 agonist?
No. An inhibitor prolongs the body's own GLP-1 into a physiological range; an agonist supplies an engineered ligand at pharmacological levels, with much larger effects.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubChemPubChem · Semaglutide (CID 56843331)pubchem.ncbi.nlm.nih.gov
- PubChemPubChem · Liraglutide (CID 16134956)pubchem.ncbi.nlm.nih.gov
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- GLP-1 Drugs Beyond Weight LossSELECT showed a 20% reduction in cardiovascular events. Heart failure, kidney and peripheral artery indications followed. What the evidence supports.
- The GIP Paradox: Why Agonism and Antagonism Both Produce Weight LossTirzepatide activates the GIP receptor. MariTide blocks it. Both produce substantial weight loss alongside GLP-1 agonism, and the field has not resolved why.
- What Is Maridebart Cafraglutide? Antibody Meets PeptideMariTide is a monoclonal antibody blocking the GIP receptor, conjugated to two GLP-1 agonists. An unusual format, and the opposite premise to tirzepatide.
- Lean Mass Loss on GLP-1 Therapy, and the BELIEVE ResultA substantial share of weight lost on GLP-1 therapy is lean mass. The BELIEVE trial cut lean loss from 7.4% to 2.9% by adding bimagrumab to semaglutide.
- What Is Cagrilintide? The Amylin Half of CagriSemaCagrilintide is a long-acting amylin analogue engineered for weekly dosing. Why native amylin could never be a drug, and what the analogue changed.